TabletsClinical Overview
Indapamide is an indole-derivative thiazide-like chlorosulfamoyl diuretic and arterial vasodilator on the WHO Model List of Essential Medicines. At antihypertensive doses, it exhibits a dual mechanism: direct vascular action (stimulating prostaglandin PGE2 synthesis and blocking calcium influx in vascular smooth muscle to reduce peripheral resistance) combined with mild distal tubular natriuresis, exerting virtually neutral effects on lipids and glucose. Indicated for essential hypertension, alone or in fixed-dose combination with ACE inhibitors (perindopril) or CCBs.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Take orally once daily in the morning with water, with or without breakfast. Sustained-release tablets must be swallowed whole without crushing or chewing.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Hypokalemia, fatigue, headache, dizziness, muscle cramps, mild nausea. Rare/Severe: Severe hypokalemia, hyponatremia, acute angle-closure glaucoma, and exacerbation of systemic lupus erythematosus.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Contraindicated in severe renal failure (anuria), severe hepatic encephalopathy, and refractory hypokalemia. Monitor serum potassium, especially in elderly patients or patients on cardiac glycosides.
Schedule H (Prescription Required)
This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, clinical diagnosis, or treatment recommendations. Always consult a registered medical practitioner or qualified cardiologist/pharmacist before initiating, altering, or substituting any cardiovascular medication.
Perindopril Erbumine 4mg + Indapamide 1.25mg Tablets
Angiotensin Converting Enzyme (ACE) Inhibitor on the WHO Model List of Essential Medicines. It blocks the conversion of angiotensin I to the potent vasoconstrictor angiotensin II, reducing peripheral arterial resistance, decreasing aldosterone secretion, and inhibiting the enzymatic degradation of bradykinin, producing potent vasodilation and cardioprotection. Indicated for essential hypertension, heart failure with reduced ejection fraction (HFrEF), post-myocardial infarction, and diabetic nephropathy.
Amlodipine + Indapamide Tablet (5/1.5 Mg)
Amlodipine (or S-Amlodipine, the pure chirally active enantiomer with lower incidence of ankle edema) is a third-generation dihydropyridine calcium channel blocker on the WHO Model List of Essential Medicines. It inhibits transmembrane influx of extracellular calcium ions into vascular smooth muscle and cardiac muscle through L-type channels, resulting in potent peripheral arterial and coronary vasodilation with an exceptionally long half-life (30-50 hours). Indicated for essential hypertension, chronic stable angina pectoris, and vasospastic (Prinzmetal's) angina.
Atenolol + Indapamide Tablet (50/2.5 Mg)
Beta-adrenergic receptor antagonist (cardioselective beta-1 blocker, non-selective beta blocker, or third-generation vasodilating beta-blocker with alpha-blockade or nitric oxide release) on the WHO Model List of Essential Medicines. It competitively blocks adrenergic stimulation, reducing heart rate, myocardial contractility, cardiac output, and renin release. Indicated for hypertension, stable angina pectoris, heart failure, cardiac arrhythmias, and post-myocardial infarction secondary prevention.
Telmisartan + Indapamide Tablet (40/1.5 Mg)
Telmisartan is a potent, non-peptide, long-acting angiotensin II type 1 (AT1) receptor antagonist on the WHO Model List of Essential Medicines. It exhibits an exceptionally long elimination half-life (around 24 hours) providing sustained 24-hour blood pressure control with high trough-to-peak ratio, and uniquely functions as a partial agonist at peroxisome proliferator-activated receptor-gamma (PPAR-gamma), improving glucose handling and lipid metabolism. Indicated for essential hypertension and cardiovascular risk reduction in patients with coronary artery disease, stroke, or diabetes with end-organ damage.